Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 11, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
There are no material changes to the company's financial position reported in this filing. The document details an increase in share interests for specific individuals following the reinvestment of dividends paid on July 6, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It strictly reports on the administrative notification of share plan transactions in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Type: Reinvestment of dividends into Ordinary Share ADRs.
- Transaction Price: $56.46 per ADR.
- Dividend Date: July 6, 2006.
- Notified Individuals: Dr. JP Garnier (503.336 shares), Dr. F Calhoun (37.071 shares), Mr. D Phelan (107.857 shares), and Mr. D Stout (52.234 shares).
- Signatory: Victoria Whyte, Authorised Signatory.